The primary factors guiding systemic adjuvant treatment decisions are disease extent and classification based on intrinsic BC subtypes: luminal A, luminal B (human epidermal growth factor receptor 2 (HER2)-negative and HER2-positive), HER2-enriched, and basal-like (triple-negative) subtypes [7]. This evidence concerns the gene ERBB2 and breast cancer.